SA
VKTX icon

Sanctuary Advisors’s Viking Therapeutics VKTX Stock Holding History

Sanctuary Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$986K Sell
25,272
-2,108
-8% -$68.1K ﹤0.01% 1458
2026
Q1 		$891K Sell
27,380
-1,469
-5% -$47.2K ﹤0.01% 1404
2025
Q4 		$1.01M Buy
+28,849
New +$1.02M 0.01% 1316
2024
Q4 		– Sell
-5,416
Closed -$285K – 2503
2024
Q3 		$285K Buy
5,416
+1,836
+51% +$108K ﹤0.01% 2030
2024
Q2 		$266K Buy
+3,580
New +$235K ﹤0.01% 2017

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Sanctuary Advisors's VKTX Position: Q2 2026 in Review

Sanctuary Advisors reduced its Viking Therapeutics (VKTX) stake by 7.7% in Q2 2026, selling an estimated $68.1K and leaving 25,272 shares worth $986K. The position accounts for ﹤0.01% of the portfolio, ranked #1458.

Sanctuary Advisors first reported a position in VKTX in Q2 2024 and has held it in 5 quarters since. The position peaked at $1.01M in Q4 2025. 434 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Sanctuary Advisors held 25,272 shares of Viking Therapeutics worth $986K as of Q2 2026.
  • Sanctuary Advisors sold 2,108 Viking Therapeutics shares in Q2 2026, an estimated $68.1K.
  • Viking Therapeutics made up ﹤0.01% of Sanctuary Advisors's portfolio in Q2 2026, its #1458 holding.
  • Sanctuary Advisors first reported a position in Viking Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • Sanctuary Advisors's Viking Therapeutics position peaked at $1.01M in Q4 2025.
  • 434 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Sanctuary Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.